Imbruvica (ibrutinib) / Royalty, Generic mfg., AbbVie, J&J  >>  Phase 1
Welcome,         Profile    Billing    Logout  

93 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imbruvica (ibrutinib) / AbbVie, J&J
NCT01292135: Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

Checkmark Interim P1b data - ASCO poster presentation
Jun 2012 - Jun 2012: Interim P1b data - ASCO poster presentation
Checkmark P1b data: relapsed or refractory CLL or SLL
May 2012 - May 2012: P1b data: relapsed or refractory CLL or SLL
Completed
1b
33
US
PCI-32765
Pharmacyclics LLC.
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
11/12
05/13
NCT01569750: A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

Checkmark In combination with R-CHOP (R-CHOP) for treatment-naive patients with CD20-positive B-cell NHL
Jul 2014 - Jul 2014: In combination with R-CHOP (R-CHOP) for treatment-naive patients with CD20-positive B-cell NHL
Checkmark For B-cell NHL
Dec 2013 - Dec 2013: For B-cell NHL
Checkmark Presentation of data (combo R-CHOP) with CD20 positive B-cell non-Hodgkin's lymphoma
More
Completed
1b
33
US, Europe
Part 1, Cohort 1, Part 1, Cohort 2, Part 1, Cohort 3, Part 2, Cohort 1, Part 2, Cohort 2
Janssen Research & Development, LLC, Pharmacyclics LLC.
CD20-positive B-cell Non-Hodgkin Lymphoma
09/14
09/14
CIRLL study, NCT03420183: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Recruiting
1b
156
US
Cirmtuzumab followed by Cirmtuzumab plus ibrutinib, UC-961, Imbruvica, Cirmtuzumab plus ibrutinib, Ibrutinib
Oncternal Therapeutics, Inc, University of California, San Diego, California Institute for Regenerative Medicine (CIRM)
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma
04/19
12/22
NCT02553941: Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Completed
1b
21
US
Azacitidine, Vidaza, Ibrutinib, BTK Inhibitor
Brian Jonas, Pharmacyclics LLC.
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation, Secondary Myelodysplastic Syndrome
05/19
11/19
NCT01644253: Phase 1b Safety and Efficacy Study of TRU-016

Hourglass Jan 2017 - Jun 2017 : From P1b trial (NCT01644253) in combination with Rituximab and Obinutuzumab in previously untreated CLL
Checkmark In combination with rituximab in pts with CLL
Dec 2013 - Dec 2013: In combination with rituximab in pts with CLL
Checkmark Presentation of data from TRU-016 + rituximab trial of expanded cohort and original cohort for first-line CLL
Nov 2013 - Nov 2013: Presentation of data from TRU-016 + rituximab trial of expanded cohort and original cohort for first-line CLL
Terminated
1b
87
US
20 mg/kg TRU-016 + Rituximab, Rituxan, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab, Gazyva, TRU-016 6-20 mg/kg + idelalisib + rituximab, Zydelig, Rituxan, TRU-016 10-20 mg/kg + ibrutinib, Imbruvica, TRU-016 10-20 mg/kg + bendamustine
Aptevo Therapeutics
Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
02/20
04/21
NCT02954406: A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Terminated
1b
43
Canada, US
TAK-659, Bendamustine, Rituximab, Gemcitabine, Lenalidomide, Ibrutinib
Millennium Pharmaceuticals, Inc.
Lymphoma, Non-Hodgkin
07/20
07/20
NCT00849654: Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Checkmark ASH 2012
Jan 2013 - Jan 2013: ASH 2012
Completed
1
66
US
PCI-32765
Pharmacyclics LLC.
B-Cell Lymphoma, B-Cell Leukemia
07/12
07/12
NCT01626651: A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants

Completed
1
21
US
Ibrutinib, Ketoconazole
Janssen Research & Development, LLC
Healthy
08/12
08/12
NCT01674322: A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants

Completed
1
6
Europe
Ibrutinib, PCI-32765
Janssen Research & Development, LLC
Healthy Participants
09/12
09/12
NCT01763021: A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants

Completed
1
18
US
PCI-32765, Rifampin
Janssen Research & Development, LLC
Healthy Participants
01/13
01/13
NCT01820936: A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765

Completed
1
52
US
Sequence 1: PCI-32765, Sequence 2: PCI-32765, Sequence 3: PCI-32765, Sequence 4: PCI-32765, Sequence 5: PCI-32765
Janssen Research & Development, LLC, Pharmacyclics LLC.
Healthy Volunteers
06/13
06/13
NCT01866033: A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants

Completed
1
8
Europe
PCI-32765 (Treatment A), PCI-32765 (Treatment B), PCI-32765 (Treatment C), 13C6 PCI-32765 (reference)
Janssen Research & Development, LLC, Pharmacyclics LLC.
Healthy Volunteer
08/13
08/13
NCT01767948: A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

Completed
1
30
US
PCI-32765
Janssen Research & Development, LLC
Hepatic Impairment
11/13
11/13
NCT01969266: A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food

Completed
1
8
US
Treatment A: PCI-32765, Treatment B: PCI-32765
Janssen Research & Development, LLC, Pharmacyclics LLC.
Healthy Volunteer
11/13
11/13
NCT01479842: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Checkmark In pts with previously untreated & relapsed/refractory NHL
Oct 2014 - Oct 2014: In pts with previously untreated & relapsed/refractory NHL
Active, not recruiting
1
48
US
BTK inhibitor PCI-32765, Bruton's tyrosine kinase inhibitor PCI-32765, PCI-32765, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, bendamustine hydrochloride, bendamustin hydrochloride, bendamustine, cytostasan hydrochloride, Treanda, pharmacogenomic studies, Pharmacogenomic Study, pharmacological study, pharmacological studies, laboratory biomarker analysis
Kami Maddocks, MD, Pharmacyclics LLC.
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
10/25
10/25
NCT02271438: A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants

Completed
1
28
Europe
Ibrutinib, Moxifloxacin, Ibrutinib-matching placebo, Moxifloxacin-matching placebo
Janssen Research & Development, LLC
Healthy
04/15
05/15
NCT01829568: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Active, not recruiting
1
33
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima
National Cancer Institute (NCI), Celgene Corporation
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
05/15
06/26
NCT02109224: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

Terminated
1
72
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, PCI-32765, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, HIV Infection, Intraocular Lymphoma, Multicentric Angiofollicular Lymphoid Hyperplasia, Nodal Marginal Zone Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Plasma Cell Myeloma, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
07/15
07/15
NCT02390609: A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults

Completed
1
40
Europe
Ibrutinib (Treatment A) [Reference], Ibrutinib (Treatment B), Ibrutinib (Treatment C), Ibrutinib (Treatment D), Ibrutinib (Treatment E), Ibrutinib (Treatment F)
Janssen Research & Development, LLC
Healthy
11/15
11/15
NCT01704963: A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

Completed
1
15
Japan
PCI-32765
Janssen Pharmaceutical K.K., Pharmacyclics LLC.
Recurrent Mature B-cell Neoplasms
11/15
02/17
NCT02638116: A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults

Completed
1
20
Europe
Ibrutinib, Omeprazole
Janssen Research & Development, LLC
Healthy
03/16
03/16
NCT02381080: Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

Completed
1
26
Canada, Europe, RoW
Ibrutinib, Imbruvica, PCI-32765, JNJ-54179060, Erythromycin, Erythrocin, Voriconazole, VFEND
Janssen Research & Development, LLC
B-Cell Chronic Lymphocytic Leukemia
06/16
06/16
NCT02841150: Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

Completed
1
102
US
IMBRUVICA (Treatment A), Ibrutinib, Ibrutinib (Treatment B)
Janssen Research & Development, LLC
Healthy
08/16
08/16
NCT02877225: Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

Completed
1
103
US
Ibrutinib, IMBRUVICA
Janssen Research & Development, LLC
Healthy
11/16
11/16
NCT02200848: Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Terminated
1
5
US
Lenalidomide, Ibrutinib, Rituximab, Ibrutinib, PCI-32765, NSC# 748645, Imbruvica, Lenalidomide, alpha-[3-aminophthalimido] glutarimide, Revlimid, CC-5013, NSC#703813, Rituximab, IDEC-C2B8, Rituxan
Georgetown University, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/17
08/17
NCT02160015: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
12
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography, Electrocardiogram, ECG, EKG, Electrocardiograms, Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima
National Cancer Institute (NCI)
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
03/17
08/26
NCT02219737: Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Completed
1
26
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Pharmacological Study, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83
National Cancer Institute (NCI)
CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
05/17
05/17
NCT02635074: Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated
1
2
US
Cytarabine, Beta-cytosine arabinoside, 1-beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-beta-D-arabinofuranosylcytosine, 2(1H)-pyrimidinone, 4-amino-1-beta-d-arabinofuranosyl, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Ibrutinib, Imbruvica, BTK Inhibitor PCI-32765, PCI-32765, CRA-032765, Idarubicin, Idamycin, Zavedos, 4-Demethoxydaunomycin, 4-Demethoxydaunorubicin, 4-DMDR
Steven E. Coutre, National Cancer Institute (NCI)
Recurrent Adult Acute Myeloid Leukemia
07/17
11/17
BIBLOS, NCT02055924: Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas

Terminated
1
85
Europe
Ibrutinib and immunochemotherapies, Ibrutinib + R-DHAP, Ibrutinib + R-DHAOx
The Lymphoma Academic Research Organisation, Janssen Pharmaceutica N.V., Belgium
B-cell Lymphoma
12/17
10/18
NCT02815059: Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

Withdrawn
1
0
US
Ibrutinib, Dasatinib, Prednisone
University of Utah, Janssen, LP
Acute Lymphoblastic Leukemia
01/18
01/18
NCT02268851: A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Checkmark From a trial for r/r CLL or MCL at EHA 2020
Jun 2020 - Jun 2020: From a trial for r/r CLL or MCL at EHA 2020
Checkmark From P1/1b trial in combination with umbralisib in CLL and mantle cell lymphoma at EHA 2020
Jun 2020 - Jun 2020: From P1/1b trial in combination with umbralisib in CLL and mantle cell lymphoma at EHA 2020
Checkmark Results in combination with ibrutinib for CLL & MCL
More
Completed
1
45
US
TGR-1202, RP5264, Umbralisib, Ibrutinib, Imbruvica, CRA-032765, PCI-32765
Dana-Farber Cancer Institute, TG Therapeutics, Inc., The Leukemia and Lymphoma Society, Blood Cancer Research Partnership
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
05/18
10/22
NCT02159755: Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

Active, not recruiting
1
28
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Pharmacological Study
National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma
06/18
12/26
NCT02914327: Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

Withdrawn
1
0
US
SNX-5422 plus ibrutinib, Imbruvica
Esanex Inc.
Cancer
07/18
07/18
NCT03301207: A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

Completed
1
25
Europe
Ibrutinib, Imbruvica, OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg, Microgynon 30, Bupropion, Midazolam
Janssen Research & Development, LLC
Leukemia, Lymphocytic, Chronic, B-Cell
07/18
12/18
NCT02556892: A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed
1
8
Japan
Ibrutinib, PCI-32765, JNJ-54179060
Janssen Pharmaceutical K.K.
Lymphocytic Leukemia
08/18
08/18
NCT02743546: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Withdrawn
1
0
NA
Duvortuxizumab, Ibrutinib
Janssen Research & Development, LLC
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell
09/18
03/20
NCT02640209: Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)

Terminated
1
20
US
CART 19
University of Pennsylvania
LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
10/18
07/19
NCT02950220: Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed
1
2
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Kami Maddocks, National Cancer Institute (NCI)
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Mediastinal Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma
11/18
01/19
NCT02973399: Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

Terminated
1
5
US
SNX-5422 plus ibrutinib, Imbruvica
Esanex Inc.
Cancer
12/18
02/19
NCT02352558: A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Completed
1
15
US
BBI608, Napabucasin, BB608, BBI-608, Dexamethasone, Bortezomib, Velcade, Imatinib, Gleevec, Ibrutinib, Imbruvica
Sumitomo Pharma America, Inc.
Hematologic Malignancy
12/18
05/19
NCT02759016: Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Completed
1
7
US
BI 836826, Ibrutinib
Boehringer Ingelheim
Leukemia, Lymphocytic, Chronic, B-Cell
06/19
07/19
NCT02966730: Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Terminated
1
2
US
Ibrutinib
Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, Pharmacyclics LLC.
Follicular Lymphoma, Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma Grade IIIa
06/19
06/19
NCT02614508: Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Terminated
1
1
US
Buparlisib, BKM120, PI3K Inhibitor BKM120, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, PCI-32765, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2
Emory University, Novartis
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
08/19
08/19
NCT03359460: Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Completed
1
4
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
Brian Jonas, Pharmacyclics LLC., Celgene, National Cancer Institute (NCI)
Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
08/19
11/19
NCT02006485: Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

Checkmark Follow-up data from the triple combination of ublituximab, umbralisib, and bendamustine in DLBCL and FL
Dec 2018 - Dec 2018: Follow-up data from the triple combination of ublituximab, umbralisib, and bendamustine in DLBCL and FL
Checkmark TG-1101 + TGR-1202 (umbralisib) + Ibrutinib Triple Combination Data in CLL & NHL at ASCO 2017
Jun 2017 - Jun 2017: TG-1101 + TGR-1202 (umbralisib) + Ibrutinib Triple Combination Data in CLL & NHL at ASCO 2017
Checkmark Triplet combination of Utuxin + TGR-1202 + bendamustine in DLBCL, FL at ASH 2016
More
Completed
1
160
US
Ublituximab + TGR-1202, Ublituximab + TGR-1202 + ibrutinib, Imbruvica, Ublituximab + TGR-1202 + bendamustine, Treanda
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
10/19
10/19
NCT02611908: Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Withdrawn
1
0
NA
ibrutinib, Imbruvica, obinutuzumab, Gazyva
Michael Choi, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia
11/19
11/20
NCT04043845: ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Withdrawn
1
0
NA
Ibrutinib, Imbruvica, LY3214996
Dana-Farber Cancer Institute, Eli Lilly and Company
Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma
02/20
02/20
NCT02537613: A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Active, not recruiting
1
54
US
Obinutuzumab, Gazyva, GA-101, Ibrutinib, Imbruvica
Dana-Farber Cancer Institute, Genentech, Inc.
Chronic Lymphocytic Leukemia
03/20
01/27
NCT01886859: Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed
1
27
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
National Cancer Institute (NCI)
Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
11/20
09/22
NCT03454165: A Study of BNC105P Combined With Ibrutinib

Completed
1
6
US
BNC105P, Ibrutinib
Dartmouth-Hitchcock Medical Center
Chronic Lymphocytic Leukemia
01/21
01/21
NCT02419560: Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

Completed
1
37
US
ABT-199 and Ibrutinib Combination, GDC-0199, venetoclax, PCI-32765
Craig Portell, MD, AbbVie
Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell
05/21
05/21
TREBL-1, ACTRN12618001541291: A study of the use of Ibrutinib in combination with donated immune cells in patients with Epstein-Barr Virus positive lymphomas

Active, not recruiting
1
20
 
Australasian Leukaemia and Lymphoma Group, Department of Health and Human Resources
EBV+ Lymphoma
 
 
NCT03876028: Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Terminated
1
10
US
Tisagenlecleucel, Ibrutinib
Novartis Pharmaceuticals
Diffuse Large B-cell Lymphoma
11/21
11/21
NCT03525925: Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

Completed
1
16
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Ohio State University Comprehensive Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm
02/20
07/22
NCT04115059: Dasatinib In Waldenström Macroglobulinemia

Terminated
1
3
US
Dasatinib, Sprycel
Jorge J. Castillo, MD, Bristol-Myers Squibb
Waldenstrom Macroglobulinemia, DASATINIB
12/21
12/21
NCT02303392: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Completed
1
34
US
Selinexor, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Pharmacological Study, pharmacological studies, Laboratory Biomarker Analysis
Jennifer Woyach, Karyopharm Therapeutics Inc
Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
04/22
04/22
CITADEL-112, NCT03424122: INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma

Completed
1
50
Europe, US
Parsaclisib, INCB050465, Rituximab, Rituxan, Bendamustine, Treanda, Bendeka, Ibrutinib, Imbruvica
Incyte Corporation
B-cell Lymphoma
06/22
06/22
NCT04439006: Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Completed
1
10
US
Best Practice, standard of care, standard therapy, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765
Jennifer Woyach, Janssen Scientific Affairs, LLC
Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
09/22
09/22
NCT02756247: A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Completed
1
37
US
Buparlisib, Ibrutinib
Memorial Sloan Kettering Cancer Center, Janssen Scientific Affairs, LLC, Novartis Pharmaceuticals
Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma
10/22
10/22
NCT04274738: A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Hourglass Jul 2020 - Dec 2020 : Initial data from the trial in combination with Mavorixafor
Completed
1
16
Europe, US
Mavorixafor, X4P-001, Ibrutinib
X4 Pharmaceuticals
Waldenstrom's Macroglobulinemia
10/22
10/22
NCT02446236: Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Active, not recruiting
1
27
US
Lenalidomide, Revlimid, Ibrutinib, Imbruvica, Rituximab, Rituxan
Hackensack Meridian Health
Mantle Cell Lymphoma
01/17
10/25
NCT03136497: A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Terminated
1
10
US
400mg ABT-199, A-1195425.0, Venetoclax, Ibrutinib, PIC-32765, Imbruvica, Rituximab, Rituxan, 800mg ABT-199
Hackensack Meridian Health, Janssen Scientific Affairs, LLC, Genentech, Inc.
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
11/20
11/20
NCT03225716: A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

Terminated
1
13
US
Ulocuplumab, BMS-936564, Ibrutinib, Imbruvica
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Waldenstrom's Macroglobulinemia
12/22
12/22
NCT02309580: Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

Completed
1
14
US
Ibrutinib
Memorial Sloan Kettering Cancer Center, Ohio State University, Pharmacyclics LLC., Janssen Biotech, Inc.
T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma
05/23
05/23
The EXPLORE Trial, NCT03219047: Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Completed
1
1
US
Best Practice, standard of care, standard therapy, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Patient Derived Xenograft, Patient-Derived Xenograft, Patient-Derived Xenograft Model, PDTX, PDX, Personalized Medicine
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
07/23
07/23
NCT03422393: Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Active, not recruiting
1
24
US
Venetoclax, Venclexta, Ibrutinib, Imbruvica
Michael Choi, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/24
08/28
ACTRN12623000822684: A Single-center, 2-arm Interventional Study to Determine the Association between the Gut Microbiome and the Pharmacokinetic Profile of Ibrutinib in Healthy Adult Volunteers.

Completed
1
20
 
BioCorteX Pty Ltd, BioCorteX Pty Ltd
Cancer
 
 
NCT03220022: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Active, not recruiting
1
46
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Pharmacological Study, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
10/24
07/26
NCT03703167: Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Active, not recruiting
1
25
US
Ibrutinib, Lenalidomide, Rituximab
Memorial Sloan Kettering Cancer Center, Pharmacyclics LLC.
Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
11/26
11/26
NCT04876092: A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

Completed
1
45
Europe
JNJ-67856633, Ibrutinib, JNJ-54179060
Janssen Research & Development, LLC
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
02/25
02/25
NCI-2018-00315, NCT03479268: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Active, not recruiting
1
18
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Pevonedistat, MLN4924, Nedd8-Activating Enzyme Inhibitor MLN4924, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Pharmacological Study
City of Hope Medical Center, National Cancer Institute (NCI)
B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
11/26
11/26
NCT03440567: Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Completed
1
16
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous Hematopoietic Cell Transplantation, autologous stem cell transplantation, Stem Cell Transplantation, Autologous, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide Phosphate, Etopophos, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
06/24
06/24
NCI-2018-00159, NCT03447808: Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Active, not recruiting
1
15
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Pharmacological Study
Jennifer Woyach
Chronic Lymphocytic Leukemia
06/26
06/26
EQUILIBRIUM, NCT03535350: Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Active, not recruiting
1
36
US
Ibrutinib, Imbruvica, Radiation, Temozolomide (TMZ), Temodar, Methazolastone
Case Comprehensive Cancer Center
Glioblastoma
04/23
12/25
iVAC-XS15-CLL01, NCT04688385: Personalized Multi-peptide Vaccination in CLL Patients

Completed
1
20
Europe
Multipeptide Vaccine+ XS15
University Hospital Tuebingen
Chronic Lymphocytic Leukemia
10/24
10/24
NCT05211336: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active, not recruiting
1
14
US
Obinutuzumab, Gazyva, Prednisone, Rayos, Deltasone, Prednisone Intensol, Lenalidomide, REVLIMID, Venetoclax, Venclexta, Venclyxto, Ibrutinib, Imbruvica, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Banophen, Nytol, Peg-filgrastim, Neulasta, CT Scan (chest, abdomen, and pelvis), Computed tomography scan, MRI, Magnetic resonance imaging, 18f-FDG-PET, F18-fluorodeoxyglucose-positron emission tomography, PET, Lumbar puncture/Ommaya tap, Bone marrow aspiration/biopsy, EKG, Electrocardiogram
National Cancer Institute (NCI)
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
06/24
06/29
NCT02787369: ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Active, not recruiting
1
3
US
ACY-1215, Ricolinostat, Ibrutinib, Imbruvica, Idelalisib, Zydelig
Dana-Farber Cancer Institute, Acetylon Pharmaceuticals Incorporated
Recurrent Chronic Lymphoid Leukemia
04/26
04/27
NCT03939182: Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Completed
1
15
US
Abexinostat, Ibrutinib
Memorial Sloan Kettering Cancer Center, Janssen Scientific Affairs, LLC, Xynomic Pharmaceuticals, Inc.
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
04/25
04/25
NCT02203526: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Recruiting
1
93
US
Isavuconazole, TEDDI, Rituximab, Cytarabine, TEDD, Ibrutinib (Arms 2, 3 and 4), Methotrexate, Ibrutinib (Arm 1 - Closed with Amendment G), Ibrutinib (Arm 4)
National Cancer Institute (NCI)
Primary Central Nervous System Lymphoma
06/26
06/27
NCT04739813: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Recruiting
1
55
US
obinutuzumab, prednisone, Revlimid, Polatuzumab, ibrutinib, venetoclax
National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
04/26
04/31
NCT03295240 / 2006-004034-32: The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Completed
1
10
US
BR-I (bendamustine, rituximab, ibrutinib), VEN (Venetoclax)
Memorial Sloan Kettering Cancer Center
Mantle Cell Lymphoma, Lymphoma
01/24
01/24
NCT03400176: VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Terminated
1
39
US
VAY736, ibrutinib, Imbruvica
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia (CLL)
09/23
09/23
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia

Completed
1
46
US, RoW
APG2575 400 mg, APG2575 600 mg, APG2575 800 mg
Ascentage Pharma Group Inc.
Waldenstrom Macroglobulinemia
02/24
08/25
NCT06788509: A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Enrolling by invitation
1
80
Europe, Japan, RoW
JNJ-75348780, JNJ-67856633, safimaltib, JNJ-54179060, ibrutinib, JNJ-64264681, JNJ-74856665, JNJ-70218902, JNJ-64619178
Janssen Research & Development, LLC
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Solid Tumor, Adult, Metastatic Castration-resistant Prostate Cancer (mCRPC)
01/28
01/28
NCT01955499: Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Active, not recruiting
1
39
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography, Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma
11/24
05/26
NCT03021460: Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Active, not recruiting
1
20
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Mayo Clinic
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
12/26
12/26
NCT04781855: Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Withdrawn
1
50
NA
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
M.D. Anderson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
02/25
02/25
NCT03702725: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Completed
1
14
US
Ibrutinib, Imbruvica, Lenalidomide, Revlimid, Dexamethasone, Decadron
Alliance Foundation Trials, LLC., Pharmacyclics LLC.
Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma
09/24
10/24
EIFEL, NCT07082868: A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Recruiting
1
26
US
ibrutinib, Epcoritamab
Memorial Sloan Kettering Cancer Center
Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma, Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)
08/28
08/28
NCT07169565: Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Not yet recruiting
1
21
NA
Ibrutinib, Bendamustine, Rituximab
Institute of Hematology & Blood Diseases Hospital, China
Waldenström Macroglobulinemia (WM)
09/28
09/28
NCT05106296: Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Recruiting
1
37
US
Indoximod, Ibrutinib, Cyclophosphamide, Etoposide, Temozolomide
Theodore S. Johnson, Augusta University, CureSearch for Children's Cancer, Rally Foundation for Childhood Cancer Research
Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain Tumor
03/28
09/28
ChiCTR2200064195: A clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma

Recruiting
1
100
 
R-BAP chemotherapy regimen and zanubrutinib ;R-BAP chemotherapy regimen and Ibrutinib
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, self-raised
mantle cell lymphoma
 
 
ChiCTR2500106492: Clinical Study on the Use of Thiotepa, Rituximab, and Dexamethasone for Induction Therapy in Primary Central Nervous System Lymphoma

Recruiting
1
30
 
Rituximab combined with thiotepa, dexamethasone, and ibrutinib or pomalidomide
Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College, Jiangsu Hengrui Pharmaceuticals Co., Ltd
Primary Central Nervous System Lymphoma
 
 

Download Options